• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call

    4/9/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology
    Get the next $GDRX alert in real time by email

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its first quarter 2025 financial results after U.S. markets close on Wednesday, May 7, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook.

    To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor relations website at https://investors.goodrx.com, where accompanying materials will be posted prior to the conference call.

    Approximately one hour after completion of the live call, an archived version of the webcast will be available on the Company's investor relations website at https://investors.goodrx.com for at least 30 days.

    About GoodRx

    GoodRx is the leading platform for medication savings in the U.S., used by nearly 30 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $85 billion on the cost of their medications.

    GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx's website regularly for important information, in addition to following GoodRx's press releases, filings with the Securities and Exchange Commission and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx's website is not incorporated by reference into, and is not a part of, this press release.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250409741987/en/

    Investor Contact

    GoodRx

    Aubrey Reynolds

    [email protected]

    Media Contact

    GoodRx

    Lauren Casparis

    [email protected]

    Get the next $GDRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GDRX

    DatePrice TargetRatingAnalyst
    8/11/2025Strong Buy → Outperform
    Raymond James
    12/4/2024$5.00Neutral
    Mizuho
    8/9/2024$10.00Outperform → Strong Buy
    Raymond James
    5/23/2024$8.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    5/16/2024$10.00Mkt Perform → Outperform
    Raymond James
    4/10/2024$9.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/25/2024$7.50 → $10.00Equal Weight → Overweight
    Wells Fargo
    3/1/2024$7.00 → $10.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $GDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GoodRx downgraded by Raymond James

    Raymond James downgraded GoodRx from Strong Buy to Outperform

    8/11/25 9:45:40 AM ET
    $GDRX
    EDP Services
    Technology

    Mizuho initiated coverage on GoodRx with a new price target

    Mizuho initiated coverage of GoodRx with a rating of Neutral and set a new price target of $5.00

    12/4/24 7:38:07 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx upgraded by Raymond James with a new price target

    Raymond James upgraded GoodRx from Outperform to Strong Buy and set a new price target of $10.00

    8/9/24 7:30:17 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Nabiey Romin covered exercise/tax liability with 1,719 shares and converted options into 4,804 shares, increasing direct ownership by 2% to 137,292 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    8/15/25 6:36:46 PM ET
    $GDRX
    EDP Services
    Technology

    Chief Accounting Officer Nabiey Romin converted options into 12,663 shares and covered exercise/tax liability with 4,531 shares, increasing direct ownership by 6% to 134,207 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    8/8/25 5:15:01 PM ET
    $GDRX
    EDP Services
    Technology

    Director Clark Ian T exercised 17,248 shares at a strike of $4.74, increasing direct ownership by 21% to 100,150 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    7/9/25 5:02:44 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wagner Scott bought $124,806 worth of shares (21,652 units at $5.76) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    12/4/23 4:35:10 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $180,423 worth of shares (30,505 units at $5.91) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/30/23 4:41:35 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $677,475 worth of shares (130,743 units at $5.18) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/17/23 7:08:30 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    SEC Filings

    View All

    SEC Form 10-Q filed by GoodRx Holdings Inc.

    10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)

    8/6/25 4:20:51 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    8/6/25 4:12:56 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SCHEDULE 13D/A filed by GoodRx Holdings Inc.

    SCHEDULE 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    7/3/25 7:23:11 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GoodRx Announces Collaboration with Novo Nordisk to Expand Access to Ozempic® and Wegovy® for $499-Per-Month

    Until today, Ozempic® has not been available to eligible self-paying patients at this price GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with Novo Nordisk, all strengths of Ozempic® (semaglutide) and Wegovy® (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective today. This collaboration significantly lowers the price available on GoodRx for two of the most in-demand GLP-1 medications nationwide, expanding access for those who lack adequate insurance coverage. Today also marks the first time Ozempic® has been made available to patients at this self-pay price.

    8/18/25 9:05:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports Second Quarter 2025 Results

    Second Quarter 2025 Revenue and Adjusted EBITDA Margin in Line with Previous Guidance; Pharma Manufacturer Solutions Revenue Increased 32% Year-Over-Year GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2025. Second Quarter 2025 Highlights Revenue of $203.1 million Net income of $12.8 million; Net income margin of 6.3% Adjusted Net Income1 of $33.9 million; Adjusted Net Income Margin1 of 16.7% Adjusted EBITDA1 of $69.4 million; Adjusted EBITDA Margin1 of 34.2% Net cash provided by operating activities of $49.6 million

    8/6/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

    Seasoned industry leader tapped to help pharma reimagine their go-to-market strategies and direct-to-patient models GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company's Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at growing and enhancing innovative partnerships across the pharmaceutical industry. Her deep cross-sector experience uniquely positions her to help revolutionize how patients access and afford their medications through the GoodRx platform. T

    7/28/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Financials

    Live finance-specific insights

    View All

    GoodRx Reports Second Quarter 2025 Results

    Second Quarter 2025 Revenue and Adjusted EBITDA Margin in Line with Previous Guidance; Pharma Manufacturer Solutions Revenue Increased 32% Year-Over-Year GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2025. Second Quarter 2025 Highlights Revenue of $203.1 million Net income of $12.8 million; Net income margin of 6.3% Adjusted Net Income1 of $33.9 million; Adjusted Net Income Margin1 of 16.7% Adjusted EBITDA1 of $69.4 million; Adjusted EBITDA Margin1 of 34.2% Net cash provided by operating activities of $49.6 million

    8/6/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for Second Quarter 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its second quarter 2025 financial results after U.S. markets close on Wednesday, August 6, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, August 7, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's inve

    7/9/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports First Quarter 2025 Results

    First Quarter 2025 Revenue In-line; Adjusted EBITDA Margin Beats Previous Guidance; Maintains Full Year 2025 Revenue Guidance Range; Raises Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2025. First Quarter 2025 Highlights Revenue of $203.0 million Net income of $11.1 million; Net income margin of 5.4% Adjusted Net Income1 of $34.4 million; Adjusted Net Income Margin1 of 16.9% Adjusted EBITDA1 of $69.8 million; Adjusted EBITDA Margin1 of 34.4% Net cash provided by operating activities of $9.4 milli

    5/7/25 4:13:00 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Leadership Updates

    Live Leadership Updates

    View All

    GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

    Seasoned industry leader tapped to help pharma reimagine their go-to-market strategies and direct-to-patient models GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company's Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at growing and enhancing innovative partnerships across the pharmaceutical industry. Her deep cross-sector experience uniquely positions her to help revolutionize how patients access and afford their medications through the GoodRx platform. T

    7/28/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Open Sources Lifecycle to Support Innovation in Software Development Velocity and Developer Productivity

    Public release of Lifecycle reflects company's commitment to transparency, innovation, and community collaboration GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced it is open-sourcing Lifecycle, a homegrown development tool designed to improve team velocity, streamline review workflows, and reduce infrastructure overhead. Lifecycle is now available to the public under the Apache 2.0 license, inviting developers and organizations to adopt, contribute to, and build upon the platform. The tool allows engineering, quality assurance, and platform teams to automatically spin up short-lived, isolated environments—known as ephemeral environments—for

    6/5/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

    Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

    3/17/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/14/24 12:29:56 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/13/24 4:30:24 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/12/24 4:02:41 PM ET
    $GDRX
    EDP Services
    Technology